Our client is a clinical stage biotech company leading the development of new therapies for rare diseases. The company’s leading program involves the treatment of X-linked Adrenoleukodystrophy, a fatal neurodegenerative disease affecting both pediatric patients and adults. The company's treatment could become the first approved treatment for the most prevalent form of the disease.
The company is now preparing for presenting a marketing authorization application (MAA) in Europe while in the US is under discussions with FDA on the path to approval. The company recently secured one of the largest rounds of EU biotech in 2022. The headquarters of our client is located near Barcelona in Spain and this position will be located in their subsidiary near Charleroi.
As the company is growing, we are currently looking for a talented CMC Specialist (in Drug Substance) to strengthen the CMC Department to support their development programs and product launch. You will report to the director of CMC activities.
This position is an excellent opportunity to contribute actively to the advancement and the growth of a Phase 3 stage company while contributing to the development of a promising treatment. This role will be key in this growing organization.
In this exciting role as CMC Drug Substance Specialist, you will be responsible for the following: